ARTIVION, INC. (AORT)
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Artivion, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 48.76M shares outstanding
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues.
Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications.
The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches.
The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Leadership
Anthony B. Semedo
Daniel J. Bevevino
Elizabeth A. Hoff
J. Patrick Mackin
Chairman, President, and Chief Executive Officer; President, Chief Executive Officer, and Chairman of the Board of Directors
Employees
2K+
Country
US
Sector
Healthcare
Website
artivion.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SVP, Regulatory and Quality | Sale | 11.5K | $286.7K | Sep 10, 2026 | |
| SVP, Regulatory and Quality | Sale | 1.5K | $38.8K | Sep 3, 2026 | |
| SVP, Regulatory and Quality | Sale | 6.5K | $177.5K | Sep 2, 2026 | |
| President & CEO | Sale | 70.0K | $2.03M | Aug 19, 2026 | |
| SVP, Regulatory and Quality | Sale | 616 | $17.6K | Aug 14, 2026 | |
| EVP, COO, CFO & Treasurer | Sale | 715 | $20.4K | Aug 14, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 6.7M | 13.7% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Oct 2025 | 6.0M | 12.3% | 13G |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.2M | 6.5% | 13F |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 3.2M | 6.5% | 13G |
MORGAN STANLEY | 2.6M | 5.2% | 13F |
Morgan Stanley · also on 13F· may incl. warrants· filed Nov 2025 | 2.1M | 4.3% | 13G |
Juniper Investment Company, LLC | 2.0M | 4.1% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | 4.1% | 13F |
FMR LLC | 2.0M | 4.0% | 13F |
FMR LLC · also on 13F· joint filing· may incl. warrants· filed Aug 2026 | 2.0M | 4.0% | 13G |
Insiders
- GREEN ANDREW MSVP, Regulatory and Quality
- Mackin James PPresident & CEO
- Berry Lance AEVP, COO, CFO & Treasurer
- Holloway Jean FSVP, General Counsel
- SEMEDO ANTHONY B.Director
- Hoff Elizabeth ADirector
- Burbank Jeffrey HDirector
- Salveson Jon WDirector
- BEVEVINO DANIEL JDirector
- ACKERMAN THOMAS FDirector
based on 48.76M shares outstanding
30d Avg
496.85K
60d Avg
572.64K
90d Avg
640.66K